par De Jager, Robert 
;Kenis, Yvon ;Brugarolas, Antonio;Hansen, Heine;Cavalli, Franco;Ryssel, H.;Siegenthaler, Pierre;Clarysse, Albert;Alberto, Pierre J L P.;Renard, Josette
Référence European journal of cancer, 15, 7, page (971-974)
Publication Publié, 1979-07
;Kenis, Yvon ;Brugarolas, Antonio;Hansen, Heine;Cavalli, Franco;Ryssel, H.;Siegenthaler, Pierre;Clarysse, Albert;Alberto, Pierre J L P.;Renard, JosetteRéférence European journal of cancer, 15, 7, page (971-974)
Publication Publié, 1979-07
Article révisé par les pairs
| Résumé : | One hundred and sixty-two patients with advanced solid tumors were treated with oral dianhydrogalactitol 30 mg/m2 daily for 10 days every 4-6 weeks. Dose limiting toxicity was hematopoietic. Eight objective responses were seen in 136 evaluable cases. Patients with gastro-intestinal cancer ( 2 13 gastric, 1 3 pancreatic, 2 23 colorectal) showed objective regressions lasting 1-12 + months. Short lasting partial remissions occurred in 2 20 lung epidermoid and 1 18 breast carcinomas. Dianhydrogalactitol has limited chemotherapeutic activity against adult solid tumors but deserves further trial in gastro-intestinal malignancies. © 1979. |
